This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Teceleukin
- DrugBank Accession Number
- DB15389
- Background
Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Teceleukin
- External IDs
- RO-236019
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Analgesics
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Biological Factors
- Central Nervous System Agents
- Cytokines
- Intercellular Signaling Peptides and Proteins
- Interleukin-2
- Interleukins
- Lymphokines
- Peptides
- Peripheral Nervous System Agents
- Proteins
- Sensory System Agents
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- H5ZRB188EI
- CAS number
- 136279-32-8
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Melanoma 1 2 Active Not Recruiting Treatment Malignant Solid Neoplasms / Metastatic Colorectal Adenocarcinoma / Metastatic Ovarian carcinoma / Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) / Platinum-Resistant Ovarian Carcinoma / Recurrent High Grade Ovarian Serous Adenocarcinoma / Recurrent Ovarian Carcinosarcoma / Refractory Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 1 1 Recruiting Treatment Clinical Stage IV Cutaneous Melanoma AJCC v8 / Cutaneous Melanoma, Stage III / IL13RA2 Positive / Metastatic Melanoma / Stage IV Cutaneous Melanoma 1 1 Recruiting Treatment Pediatric Solid Tumors With Lung Metastases / Refractory/Relapse Neuroblastoma 1 1, 2 Terminated Treatment Acute Myeloid Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 15:24 / Updated at February 21, 2021 18:55